Amylyx Q2 net loss $43.4M; Phase 3 PBH topline data expected late Aug/early Sep 2026

Amylyx Pharmaceuticals, Inc.

2026-Q2 EPS reported -$0.76

Net loss of $43.4M ($0.39 per share) vs $41.4M ($0.46 per share) in Q2 2025.
Cash, equivalents, and short-term investments $250.8M at June 30, 2026; runway into 2028.
R&D expenses $23.8M (down from $27.2M); SG&A $21.9M (up from $15.6M) on legal and commercial investment.
Last participant completed final visit in Phase 3 LUCIDITY trial of avexitide in PBH; topline data on track for late Aug/early Sep 2026.
Expanded Access Program for avexitide initiated; second research collaboration with Gubra A/S announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.